Respiratory

Researchers conducted a review of pharmacist interventions and their ability to impact the outcomes of patients with COPD.

Researchers determined the impact COVID-19 interventions had on Danish children’s incidence of RSV, influenza, and invasive pneumococcal disease.

This study is the first to compare 2 biologics for patients with chronic rhinosinusitis with nasal polyps and coexisting asthma.

There were more fires in the span of a 13-year period from 2005 to 2018 than in the previous 2 decades.

Approval comes from positive results in the MATINEE and METREX phase III trials, with data showing a significant reduction in annual rates of COPD exacerbations among patients.

Currently, the recommendation is for patients 75 years and older and those aged 60 to 74 years with an increased risk of severe respiratory syncytial virus.

Conflicting study findings show various associations between asthma and COVID-19; further data are needed.

Patients with pulmonary arterial hypertension (PAH) received the maximum tolerated dose of background therapy with sotatercept or the placebo to the therapy.

GSK announced its ANCHOR-1 and ANCHOR-2 phase 3 trial results for depemokimab’s efficacy and safety in treating patients with chronic rhinosinusitis with nasal polyps.

The results of this study show that the concurrent presence of asthma and obesity did not synergistically amplify inflammation in children with both asthma and overweight/obesity.

The next-gen molecular Metrix was given emergency use authorization for its ability to test for SARS-CoV-2 and influenza A and B viruses.

The combination includes 2 previously approved vaccines to target the 5 major serogroups of Neisseria meningitidis.

With the acceptance of the new drug application and granting priority review, the target action date is August 12, 2025.

In their exploration of 2 separate respiratory virus seasons, researchers examined the severity of illness for SARS-CoV-2, influenza, and respiratory syncytial virus.

As wildfires ravage Los Angeles County, pharmacists can provide crucial support to their patients.

Patients who receive either Pfizer or GSK’s respiratory syncytial virus vaccine may be at increased risk of Guillain-Barré syndrome.

Researchers compared simultaneous and sequential administration of the mRNA COVID-19 and inactivated influenza vaccines.

Zepbound from Eli Lilly is the first and only prescription medicine approved by the FDA for adults with obstructive sleep apnea and obesity.

Drug Topics met with Lourdes Cross, PharmD, BCACP, CDCES, to discuss pharmacists’ role in managing patients’ chronic obstructive pulmonary disease.

Ruth Carrico, PhD, DNP, APRN, sat down with Drug Topics to discuss the importance of COVID-19 and influenza vaccination.

Women experiencing later menopause may face a heightened risk of asthma, underscoring the possible role of estrogen in the development of the condition.

Pharmacist education can positively impact patient counseling around vaccinations in older adults.

Pharmacist management of chronic conditions can lead to improved patient outcomes.

Three RSV vaccines are currently FDA approved for use in adults aged 60 or older.

On June 26, 2024, the FDA approved ensifentrine (Ohtuvayre) for the treatment of COPD.